DMDouglas J. Matthies

Douglas J. Matthies

*This is an algorithmically generated author record based on publicly available information.

Douglas J. Matthies has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Angélica Fierro

    Pontificia Universidad Católica de Chile

    2 shared publications
  • Gerald Zapata-Torres

    Advanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina Universidad de Chile Santiago Chile

    2 shared publications
  • Agustín Nuñez

    Advanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina (Y.F., G.Z.-T., A.N., L.A., C.H.-F., Z.P., M.C., M.J.K., S.L.), Centro de Modelamiento Molecular, Biofísica y Bioinformática (CM2B2)

    1 shared publication
  • Bruce Kennedy Cassels

    Chemobiodynamics Laboratory, Department of Chemistry, Faculty of Sciences

    1 shared publication
  • Bárbara Donoso

    Recombinant Antibody and Immune-oncology laboratory, Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM)

    1 shared publication
  • Carolina Hernández-Fuentes

    Advanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina (Y.F., G.Z.-T., A.N., L.A., C.H.-F., Z.P., M.C., M.J.K., S.L.), Centro de Modelamiento Molecular, Biofísica y Bioinformática (CM2B2)

    1 shared publication

Latest Publications

  • Enhancing the Affinity of a Novel Selective scFv for Soluble ST2 through Computational Design

    by Douglas J. Matthies, Pedro Novoa-Gundel, Gonzalo Vásquez, Karen Dubois-Camacho, Marjorie De la Fuente López, Bárbara Donoso, Karen Toledo-Stuardo, Matías Gutiérrez-González, Glauben Landskron, Silvana Valdebenito-Silva, et al.

    Suppression of Tumorigenicity 2 (ST2) is a member of the IL-1 receptor family, which includes transmembrane (ST2L) and soluble (sST2) isoforms. sST2 functions as a decoy receptor for Interleukin-33 (IL-33), thereby blocking the activation of the IL-33/ST2L signaling axis, which is essential for tissue repair and immune regulation. Clinical evidence indicates that elevated sST2 levels are associated with increased disease severity in conditions such as ulcerative colitis (UC), cardiovascular disease, and asthma. However, current antibodies cannot reliably distinguish between sST2 and its membrane-bound isoform ST2L, limiting their effectiveness for diagnostic and therapeutic use. To address this limitation, we developed an antibody that selectively targets sST2. Using a phage display library, we identified a single-chain variable fragment (scFv) with high specificity for a unique five amino acid sequence (SKECF) located at the C-terminus of sST2. Our parental scFv showed high selectivity for sST2 with minimal cross-reactivity to ST2L, as demonstrated by both flow cytometry and immunoprecipitation. Molecular simulations identified key binding residues, allowing the design of four scFv mutants, three of which displayed improved binding in surface plasmon resonance (SPR) analyses. The A183YL2 mutant exhibited a 3.4-fold increase in binding affinity, while G100WH3 demonstrated reduced binding due to unfavorable conformations. This study presents an anti-sST2 scFv with enhanced specificity and affinity, offering a promising tool for the diagnosis and treatment of inflammatory diseases, in which sST2 interferes with IL-33-mediated tissue repair.


  • Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity

    by Yvo Flores, Gerald Zapata-Torres, Agustín Nuñez, Douglas J. Matthies, Larissa Alemán, Carolina Hernández-Fuentes, Gina Sánchez, Eyleen Araya, Fanny Guzman, Zully Pedrozo, et al.


  • 5-HT2 Receptor Subfamily and the Halogen Bond Promise

    by Angélica Fierro, Douglas J. Matthies, Bruce K. Cassels, Pablo Jaque, Gerald Zapata-Torres

    The binding of C-4-halogenated 1-(4-X-2,5-dimethoxyphenyl)-2-aminopropane (DOX) serotonin agonist psychedelics at all three 5-HT2 receptor subtypes is up to two orders of magnitude stronger for X = Cl, Br, or I (but not F) than when C-4 bears a hydrogen atom and more than expected from their hydrophobicities. Our docking and molecular dynamics simulations agree with the fact that increasing the polarizability of halogens results in halogen–oxygen distances to specific backbone C═O groups, and C–X···O angles, in ranges expected for halogen bonds (XBs), which could contribute to the high affinities observed. Good linear correlations are found for each receptor type, indicating that the binding pocket–ligand affinity is enhanced as the XB interaction becomes stronger (i.e., I ≈ Br > Cl > F). It is also striking to note how the linear equations unveil that the receptor’s response on the strength of the XB interaction is quite similar among 5-HT2A and 5-HT2C, whereas the 5-HT2B’s sensitivity is less. The calculated dipole polarizabilities in the binding pocket of the receptors reflect the experimental affinity values, indicating that less-polarizable and harder binding sites are more prone to XB formation.